Chantix® | Shim Clinic, Singapore
|
|
Summary
Chantix® | Shim Clinic, Singapore: Quit/stop smoking with the medication varenicline (Champix®/Chantix®). Smoking cessation clinic, Singapore. Private and confidential service. Definitions, references, and latest news.
Description
Quit smoking with the medication varenicline (Champix® / Chantix®). Revolutionary new way to stop smoking at our smoking cessation clinic. Get away from the harmful effects of smoking, without feeling the effects of withdrawal! Smoking cessation program cost: | Item | Price | | Champix® starter pack | SG$107 | | Champix® 2 week continuation pack x5 | SG$600 | | Consultation | SG$38 | | Total cost: | SG$745 |
References
Latest News
Meta-analysis shows no cardiac risk with varenicline
Tue, 15 May 2012 00:00:00 +0100 | MedWire News - Cardiology
There is no significant increase in serious adverse cardiovascular events associated with the use of varenicline for smoking cessation, a US meta-analysis published in the BMJ shows. (Source: MedWire News - Cardiology)
Evaluation of a drop‐in rolling‐group model of support to stop smoking
Tue, 08 May 2012 04:00:00 +0100 | Addiction
Conclusions A wholly state‐reimbursed clinical stop‐smoking service providing behavioural support and medication in a region of high economic and social disadvantage has reached a significant proportion of the smoking population. Long‐term success rates are lower than are found typically in clinical trials, but higher than would be expected if the smokers were to try and quit unaided. Research is needed into how to improve on the success rates achieved. (Source: Addiction)
Meta-analysis finds no significant increased risk of serious CV events in patients using varenicline for tobacco cessation
Tue, 08 May 2012 04:00:00 +0100 | NeLM - News
Source: BMJ
Area: News
According to the results of a systematic review and meta-analysis published early online in the British Medical Journal (BMJ), the use of varenicline to aid in smoking cessation is not associated with an increased risk of serious cardiovascular (CV) events.
The authors note that a previous meta-analysis of the safety of varenicline concluded that it increased the risk of CV serious adverse events by 72%. Doubts about these conclusions were however raised due to various methodological issues, including the exclusion of trials with no events, the inclusion of adverse events way beyond the treatment period, and use of the Peto odds ratio (which has shown bias under conditions of imbalance design and rate events; present in most of the...
Chantix May Help Heavy Drinkers Cut Down
Tue, 08 May 2012 04:00:00 +0100 | About.com Alcoholism
(Source: About.com Alcoholism)
EUROACTION PLUS: Varenicline ---- in smoking cessation
Mon, 07 May 2012 13:45:00 +0100 | theHeart.org
In a follow-up to EUROACTION, with the exception that the patients had the option of receiving varenicline, researchers show that a comprehensive, family-based program can reduce smoking rates in high-risk patients and those with vascular disease. (Source: theHeart.org)
A Randomized Trial of Varenicline (Chantix) for the Treatment of Spinocerebellar Ataxia Type 3
Mon, 07 May 2012 04:00:00 +0100 | Neurology
(Source: Neurology)
Varenicline: Manic relapse: case report
Sun, 06 May 2012 13:33:42 +0100 | Reactions
(Source: Reactions)
Varenicline: Psychosis: case report
Sun, 06 May 2012 13:33:42 +0100 | Reactions
(Source: Reactions)
Reanalyzed Chantix Data Yield Smaller CV Risk, New Controversy
Fri, 04 May 2012 04:00:00 +0100 | Physician's First Watch current issue
(Source: Physician's First Watch current issue)
|